title: [Efficacy and safety evaluation of two insulin treatment protocols using a continuous glucose monitoring system].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of two insulin treatment protocols using a continuous glucose monitoring system.
  
  
  METHODS
  Type 2 diabetic patients mellitus with unsatisfactory control of fasting blood glucose by oral antidiabetic drugs were included in the study. The patients were randomized into two groups to receive bedtime injection of glargine and oral antidiabetic drugs (group A) or injection of Novolin 30 R twice a day (group B) for 12 weeks. The insuline dose was adjusted according to fasting blood glucose till discharge. Continuous glucose monitoring system was used to record the average blood glucose, fasting blood glucose, 2 h postprandial blood glucose, AUCPG ≥ 10.0 mmol/L%, HbA1c and C peptide, bedtime blood glucose, 3:00 AM blood glucose, the incidence of hypoglycemia and body mass index.
  
  
  RESULTS
  The average blood glucose, fasting blood glucose, 2 h postprandial blood glucose, AUCPG ≥ 10.0 mmol/L% and HbA1c was significantly decreased and C peptide significantly increased in the two groups after the treatments. The patients in glargine group showed better improvement with a significantly lower incidence of hypoglycemia than those in Novolin 30 R group. BMI underwent no significant changes in the two groups after the treatments.
  
  
  CONCLUSIONS
  Glargine therapy better mimics the physiological insulin secretion patterns, and when combined with oral antidiabetic drugs, can be more effective and safer than premixed insulin.
authors.affiliation: Department of Endocrinology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. doctor_cy@163.com
authors.forename: Ying
authors.initials: Y
authors.lastname: Cao
authors.forename: Yuan-yuan
authors.initials: YY
authors.lastname: Zhang
authors.forename: Yao-ming
authors.initials: YM
authors.lastname: Xue
authors.forename: Hui-yan
authors.initials: HY
authors.lastname: Zeng
authors.forename: Bo
authors.initials: B
authors.lastname: Zhu
authors.forename: Cui-hua
authors.initials: CH
authors.lastname: Xie
authors.forename: Xiang-rong
authors.initials: XR
authors.lastname: Luo
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis*; D015190:Blood Glucose Self-Monitoring / Q000379:methods*; D003199:Computer Systems; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D018670:Monitoring, Ambulatory
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting